Current constitutional documents

Click here

Most recent admission document

Click here

Details of Any Other Exchanges or Trading Platforms

The company is not quoted on any other exchanges or trading platforms

Details of any Restrictions on the Transfer of Securities

There are no restrictions on the transfer of Abingdon Health securities

Whether the Company is subject to the UK City Code on Takeovers and Mergers

The company is subject to the UK City Code on Takeovers and Mergers

Country of Incorporation and Main Country of Operation

Abingdon Health was incorporated in England and Wales on 16 January 2008 (Registration No. 06475379) and is headquartered in York, UK, with an additional site in Doncaster.

Number of Securities in Issue

Issued share capital consists of 95,699,114 ordinary shares of 0.025p each.

AIM securities not in public hands

In so far as the Company is aware, the percentage of AIM securities not in public hands is: 63.49%.

Significant Shareholders (3% or over)

Shareholder Ordinary Shares Issued Share Capital (%)
Enterprise Ventures (General Partner NPIF YHTV Equity) Ltd 18,071,164 18.88%
Chris Hand 11,228,868 11.73%
Catenalucis LLC 7,266,264 7.59%
Chris Yates 6,513,844 6.81%
Thornapple LLP 6,113,124 6.39%
Hargreaves Lansdown Asset Mgt 4,212,913 4.40%
Touchstone Innovations Businesses LLP 4,164,756 4.35%
AXA Investment Mgrs 3,600,000 3.76%
University of Birmingham 3,454,496 3.61%

This information was last updated on 16th June 2021.

Description of business

Click here

Board and Governance

Click here

Documents and Reports

Click here

Regulatory Announcements

Click here


Nominated advisor and Broker:
N+1 Singer
One Bartholomew Lane
London EC2N 2AX

Solicitors to the company:
Bristows LLP
100 Victoria Embankment
London EC4Y 0DH

Solicitors to nominated advisors:
Fieldfisher LLP
Riverbank House
2 Swan Lane
London EC4R 3TT

Reporting Accountant and Auditor:
Central Square
29 Wellington Street
Leeds LS1 4DL

Link Group
The Registry
34 Beckenham Road
Kent BR3 4TU

Public Relations:
Consilium Strategic Communications
41 Lothbury

For all investor relations enquiries, please contact Consilium Strategic Communications at: